Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis
Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of Plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy.
1. A method for inhibiting, delaying or reducing tumor growth in a subject with cancer, comprising administering to the subject a combination of an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) and an effective amount of an anti-Lymphocyte Activation Gene 3 (LAG-3) antibody or antigen-binding fragment thereof; or a combination of an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D), an anti-LAG-3 antibody or antigen-binding fragment thereof, and another antibody or antigen-binding fragment thereof that inhibits an immune checkpoint blockade;
wherein the antibody or antigen-binding fragment thereof that specifically binds to SEMA4D comprises a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NO: 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NO: 14, 15, and 16, respectively; and
wherein administration of the combination results in enhanced therapeutic efficacy relative to administration of the anti-SEMA4D antibody or the anti-LAG-3 antibody alone.
2. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof that specifically binds to SEMA4D inhibits SEMA4D interaction with its receptor.
3. The method of claim 2 , wherein the receptor is Plexin-B1.
4. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof that specifically binds to SEMA4D inhibits SEMA4D-mediated Plexin-B1 signal transduction.
5. The method of claim 1 , wherein the cancer is selected from the group consisting of carcinoma, lymphoma, blastoma, sarcoma, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastrointestinal cancer, gastric cancer, pancreatic cancer, neuroendocrine cancer, glioblastoma, cervical cancer, ovarian cancer, bladder cancer, brain cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial carcinoma, uterine carcinoma, esophageal cancer, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, head and neck cancer, and a combination thereof.
6. The method of claim 1 , wherein the VH and VL comprise, respectively, SEQ ID NO: 9 and SEQ ID NO: 17, or SEQ ID NO: 10 and SEQ ID NO: 18.
7. The method of claim 1 , wherein a combination of an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) and an effective amount of an anti-LAG-3 antibody or antigen-binding fragment thereof is administered to the subject.
8. The method of claim 7 , wherein the antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) and the anti-LAG-3 antibody or antigen-binding fragment thereof are administered separately or concurrently.
9. The method of claim 1 , wherein a combination of an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D), an effective amount of an anti-LAG-3 antibody or antigen-binding fragment thereof, and an effective amount of another antibody or antigen-binding fragment thereof that inhibits an immune checkpoint blockade is administered to the subject.
10. The method of claim 9 , wherein the antibody or antigen-binding fragment thereof that inhibits an immune checkpoint blockade is an anti-Programmed Cell Death 1 (PD-1) antibody or antigen-binding fragment thereof.
11. The method of claim 10 , wherein the antibody or antigen-binding fragment thereof that specifically binds to Semaphorin-4D (SEMA4D), the anti-LAG-3 antibody or antigen-binding fragment thereof, and anti-PD-1 antibody or antigen-binding fragment thereof are administered separately or concurrently.
12. The method of claim 1 , wherein the administration of the combination results in an enhanced level of interferon-gamma (IFNγ) in the tumor relative to administration of the anti-SEMA4D antibody or the anti-LAG-3 antibody alone.
13. A method for treating cancer in a subject in need thereof, said method comprising administering to the subject a combination of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D), an effective amount of an anti-PD-1 antibody and an effective amount of an anti-LAG-3 antibody; wherein the antibody or antigen-binding fragment thereof that specifically binds to SEMA4D comprises a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NO: 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NO: 14, 15, and 16, respectively; and wherein administration of the combination results in enhanced therapeutic efficacy relative to administration of the anti-SEMA4D antibody or the anti-LAG-3 antibody alone.